Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 650

  • The following term was ignored: ((
  • See the search details.
1.

What Papers Are People Citing and What Are People Reading?

Lindsley CW.

ACS Chem Neurosci. 2018 Sep 19;9(9):2097-2098. doi: 10.1021/acschemneuro.8b00438. No abstract available.

PMID:
30227714
2.

Antidepressant potential of metabotropic glutamate receptor mGlu2 and mGlu3 negative allosteric modulators.

Joffe ME, Conn PJ.

Neuropsychopharmacology. 2018 Sep 10. doi: 10.1038/s41386-018-0192-8. [Epub ahead of print] No abstract available.

PMID:
30202048
3.

Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators.

Yohn SE, Foster DJ, Covey DP, Moehle MS, Galbraith J, Garcia-Barrantes PM, Cho HP, Bubser M, Blobaum AL, Joffe ME, Cheer JF, Jones CK, Lindsley CW, Conn PJ.

Mol Psychiatry. 2018 Aug 16. doi: 10.1038/s41380-018-0206-2. [Epub ahead of print]

PMID:
30116027
4.

Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M1 Positive Allosteric Modulators.

Engers JL, Bender AM, Kalbfleisch JJ, Cho HP, Lingenfelter KS, Luscombe VB, Han C, Melancon BJ, Blobaum AL, Dickerson JW, Rook JM, Niswender CM, Emmitte KA, Conn PJ, Lindsley CW.

ACS Chem Neurosci. 2018 Aug 9. doi: 10.1021/acschemneuro.8b00311. [Epub ahead of print]

PMID:
30086237
5.

Corrigendum to "Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides" [Bioorg. Med. Chem. Lett. 27(23) (2017) 5179-5184].

Tarr JC, Wood MR, Noetzel MJ, Melancon BJ, Lamsal A, Luscombe VB, Rodriguez AL, Byers FW, Chang S, Cho HP, Engers DW, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Jeffrey Conn P, Bridges TM, Lindsley CW.

Bioorg Med Chem Lett. 2018 Sep 15;28(17):3014. doi: 10.1016/j.bmcl.2018.07.022. Epub 2018 Jul 31. No abstract available.

PMID:
30076050
6.

Mutual activation of glutamatergic mGlu4 and muscarinic M4 receptors reverses schizophrenia-related changes in rodents.

Cieślik P, Woźniak M, Rook JM, Tantawy MN, Conn PJ, Acher F, Tokarski K, Kusek M, Pilc A, Wierońska JM.

Psychopharmacology (Berl). 2018 Jul 27. doi: 10.1007/s00213-018-4980-y. [Epub ahead of print]

PMID:
30054675
7.

The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease.

Doria JG, de Souza JM, Silva FR, Olmo IG, Carvalho TG, Alves-Silva J, Ferreira-Vieira TH, Santos JT, Xavier CQS, Silva NC, Maciel EMA, Jeffrey Conn P, Ribeiro FM.

J Neurochem. 2018 Jul 20. doi: 10.1111/jnc.14555. [Epub ahead of print]

PMID:
30028018
8.

New 2017 Data and Statistics for Pharmaceutical Products.

Lindsley CW.

ACS Chem Neurosci. 2018 Jul 18;9(7):1518-1519. doi: 10.1021/acschemneuro.8b00320. No abstract available.

PMID:
30016875
9.

2018: A New Impact Factor and an Expanded Cast of Associate Editors.

Lindsley CW.

ACS Chem Neurosci. 2018 Jul 18;9(7):1517. doi: 10.1021/acschemneuro.8b00318. No abstract available.

PMID:
30016874
10.

Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu4 positive allosteric modulators that mitigate CYP1A2 induction liability.

Engers DW, Bollinger SR, Engers JL, Panarese JD, Breiner MM, Gregro A, Blobaum AL, Bronson JJ, Wu YJ, Macor JE, Rodriguez AL, Zamorano R, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR.

Bioorg Med Chem Lett. 2018 Aug 15;28(15):2641-2646. doi: 10.1016/j.bmcl.2018.06.034. Epub 2018 Jun 19.

PMID:
29958762
11.

DARK Classics in Chemical Neuroscience: Phencyclidine (PCP).

Bertron JL, Seto M, Lindsley CW.

ACS Chem Neurosci. 2018 Jul 17. doi: 10.1021/acschemneuro.8b00266. [Epub ahead of print]

PMID:
29953199
12.

Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease.

Covey DP, Dantrassy HM, Yohn SE, Castro A, Conn PJ, Mateo Y, Cheer JF.

Neuropsychopharmacology. 2018 Jun 1. doi: 10.1038/s41386-018-0107-8. [Epub ahead of print]

PMID:
29925886
13.

Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992.

Kharade SV, Kurata H, Bender AM, Blobaum AL, Figueroa EE, Duran A, Kramer M, Days E, Vinson P, Flores D, Satlin LM, Meiler J, Weaver CD, Lindsley CW, Hopkins CR, Denton JS.

Mol Pharmacol. 2018 Aug;94(2):926-937. doi: 10.1124/mol.118.112359. Epub 2018 Jun 12.

PMID:
29895592
14.

Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic Analysis.

Friggeri L, Hargrove TY, Wawrzak Z, Blobaum AL, Rachakonda G, Lindsley CW, Villalta F, Nes WD, Botta M, Guengerich FP, Lepesheva GI.

J Med Chem. 2018 Jul 12;61(13):5679-5691. doi: 10.1021/acs.jmedchem.8b00641. Epub 2018 Jun 25.

PMID:
29894182
15.

Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies.

Joffe ME, Centanni SW, Jaramillo AA, Winder DG, Conn PJ.

ACS Chem Neurosci. 2018 Sep 19;9(9):2188-2204. doi: 10.1021/acschemneuro.8b00200. Epub 2018 Jun 8.

PMID:
29792024
16.

Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor.

Khajehali E, Valant C, Jörg M, Tobin AB, Conn PJ, Lindsley CW, Sexton PM, Scammells PJ, Christopoulos A.

Biochem Pharmacol. 2018 Aug;154:243-254. doi: 10.1016/j.bcp.2018.05.009. Epub 2018 May 17.

17.

The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core.

Bertron JL, Cho HP, Garcia-Barrantes PM, Panarese JD, Salovich JM, Nance KD, Engers DW, Rook JM, Blobaum AL, Niswender CM, Stauffer SR, Conn PJ, Lindsley CW.

Bioorg Med Chem Lett. 2018 Jul 1;28(12):2175-2179. doi: 10.1016/j.bmcl.2018.05.009. Epub 2018 May 5.

PMID:
29754948
18.

Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.

Felts AS, Rodriguez AL, Morrison RD, Blobaum AL, Byers FW, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1679-1685. doi: 10.1016/j.bmcl.2018.04.053. Epub 2018 Apr 22.

PMID:
29705142
19.

A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity.

Rook JM, Bertron JL, Cho HP, Garcia-Barrantes PM, Moran SP, Maksymetz JT, Nance KD, Dickerson JW, Remke DH, Chang S, Harp JM, Blobaum AL, Niswender CM, Jones CK, Stauffer SR, Conn PJ, Lindsley CW.

ACS Chem Neurosci. 2018 Sep 19;9(9):2274-2285. doi: 10.1021/acschemneuro.8b00131. Epub 2018 May 8.

PMID:
29701957
20.

Classics in Chemical Neuroscience: Risperidone.

Chopko TC, Lindsley CW.

ACS Chem Neurosci. 2018 Jul 18;9(7):1520-1529. doi: 10.1021/acschemneuro.8b00159. Epub 2018 May 11.

PMID:
29695153

Supplemental Content

Loading ...
Support Center